The story has been updated to include comments from NeoGenomics' conference call on Wednesday.

NEW YORK (GenomeWeb) – NeoGenomics on Wednesday said that its fourth quarter revenues more than doubled year over year as clinical genetic test volumes also shot up, driven by the inclusion of Clarient's results.

NeoGenomics acquired Clarient from GE Healthcare Life Sciences at the end of 2015.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.